Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IRINA O SHANIDZE

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1518977198
CMS profile
250686
Location
FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,253.25

115 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,248.99 113
Education $4.26 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IRINA O SHANIDZE

NPI 1518977198 · CMS profile ID 250686

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518977198?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IRINA O SHANIDZE, NPI 1518977198, CMS profile ID 250686. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518977198?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). IRINA O SHANIDZE, NPI 1518977198, CMS profile ID 250686. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518977198?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
IRINA O SHANIDZE, NPI 1518977198, CMS profile ID 250686, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1518977198?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

115 matching records · $2,253.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 115 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 115.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $20.5508/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598782 CMS
CSL Behring $18.4608/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820279729 CMS
E.R. Squibb & Sons, L.L.C. $11.3908/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783401015 CMS
Insmed, Inc. $11.4908/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851727995 CMS
GlaxoSmithKline, LLC. $7.9207/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802215523 CMS
Mallinckrodt Hospital Products Inc. $11.7607/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845379397 CMS
Regeneron Healthcare Solutions, Inc. $16.4007/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809623927 CMS
CSL Behring $20.2507/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820279717 CMS
AstraZeneca Pharmaceuticals LP $13.6807/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829622433 CMS
GlaxoSmithKline, LLC. $5.7507/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802918845 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.4207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598784 CMS
AstraZeneca Pharmaceuticals LP $11.0806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829799555 CMS
Teva Pharmaceuticals USA, Inc. $16.9906/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839605817 CMS
AstraZeneca Pharmaceuticals LP $13.7806/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830168835 CMS
HARMONY BIOSCIENCES LLC $19.0406/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853082431 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.2206/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598786 CMS
AstraZeneca Pharmaceuticals LP $13.7406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829615981 CMS
CSL Behring $19.5506/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820279705 CMS
JAZZ PHARMACEUTICALS INC. $15.6506/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845592485 CMS
GlaxoSmithKline, LLC. $11.1106/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802596401 CMS
ARBOR PHARMACEUTICALS, INC. $14.7106/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830925023 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.1805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598788 CMS
AstraZeneca Pharmaceuticals LP $11.2505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829774853 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.2905/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598790 CMS
United Therapeutics Corporation $16.9705/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839128611 CMS
GlaxoSmithKline, LLC. $10.8205/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802938475 CMS
CSL Behring $19.1805/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820279699 CMS
Teva Pharmaceuticals USA, Inc. $16.2605/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839605815 CMS
AstraZeneca Pharmaceuticals LP $14.1505/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829975035 CMS
JAZZ PHARMACEUTICALS INC. $16.4505/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845584845 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.6804/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598792 CMS
Philips Electronics North America Corporation $19.6904/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853235809 CMS
United Therapeutics Corporation $16.0704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839128613 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5604/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598794 CMS
CSL Behring $2.1304/14/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820279627 CMS
CSL Behring $16.1004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820279687 CMS
Insmed, Inc. $12.1604/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851727997 CMS
Mylan Specialty L.P. $20.7003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965408681 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.2403/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598796 CMS
Grifols USA, LLC $91.2503/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846763207 CMS
Teva Pharmaceuticals USA, Inc. $14.8903/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839605813 CMS
HARMONY BIOSCIENCES LLC $23.8103/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853082395 CMS
CSL Behring $16.9003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820279639 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.4903/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598798 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.2103/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598800 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1803/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763598802 CMS
AstraZeneca Pharmaceuticals LP $11.9703/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829510611 CMS
GlaxoSmithKline, LLC. $2.3702/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801697641 CMS
GlaxoSmithKline, LLC. $11.5002/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803173189 CMS
AstraZeneca Pharmaceuticals LP $30.7102/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829932013 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,809.78 71
PY2020 $1,603.73 90
PY2021 $2,253.25 115
PY2022 $4,038.70 118
PY2023 $6,310.35 129
PY2024 $2,650.95 93
PY2025 $1,797.54 98

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $364,169.99 24
PY2024 Principal investigator $419,950.22 22
PY2023 Principal investigator $313,178.40 20
PY2022 Principal investigator $92,084.74 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $12,611.00 11/21/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639524
Principal investigator 1 Genentech, Inc. $9,240.00 11/21/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639528
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,346.88 10/16/2025 Non-covered Recipient Entity
PRISM HOLDINGS LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185553219
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,499.02 10/15/2025 Non-covered Recipient Entity
PRISM HOLDINGS LLC
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185553217
Principal investigator 1 Genentech, Inc. $4,638.00 10/02/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639521
Principal investigator 1 Genentech, Inc. $12,461.00 09/09/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639517
Principal investigator 1 Genentech, Inc. $28,753.00 08/12/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639513
Principal investigator 1 AstraZeneca Pharmaceuticals LP $52,040.81 06/16/2025 Non-covered Recipient Entity
PRISM HOLDINGS LLC
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185553213
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,190.04 06/06/2025 Non-covered Recipient Entity
PRISM HOLDINGS LLC
A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids No dispute reported 06/30/2026 1185553235
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,947.55 05/28/2025 Non-covered Recipient Entity
PRISM HOLDINGS LLC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185553221
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,644.85 05/28/2025 Non-covered Recipient Entity
PRISM HOLDINGS LLC
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185553233
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,671.88 05/21/2025 Non-covered Recipient Entity
PRISM HOLDINGS LLC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 No dispute reported 06/30/2026 1185553231
Principal investigator 1 Genentech, Inc. $10,454.00 05/07/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE O
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211639502
Principal investigator 1 Genentech, Inc. $24,852.00 05/06/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE O
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639498
Principal investigator 1 AstraZeneca UK Limited $15,140.12 04/28/2025 Non-covered Recipient Entity
PRISM HOLDINGS LLC
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185553215
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,464.05 04/25/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185553227
Principal investigator 1 AstraZeneca Pharmaceuticals LP $724.50 04/23/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185553229
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,950.91 04/04/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185553209
Principal investigator 1 Genentech, Inc. $22,709.00 02/19/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211639509
Principal investigator 1 Genentech, Inc. $7,682.00 02/06/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211639505
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,338.30 01/31/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185553225
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,204.89 01/17/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 No dispute reported 06/30/2026 1185553207
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,906.62 01/17/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185553223
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,699.57 01/08/2025 Non-covered Recipient Entity
PULMONARY RESEARCH INSTITUTE OF SOUTHEAST MICHIGAN
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185553211